Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the CalDerm 2024 NorCal Conference at the Meritage Resort & Spa from May 3-5 in Napa, CA.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Xstrahl 200, a modern orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and selective benign conditions at the European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting in Glasgow, UK, May 3-7, 2024, stand # 1070.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the AOCD 2024 meeting, in Scottsdale, AZ. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. Visit Xstrahl at AOCD 2024, booth # 22 at the Westin Kierland from April 11-14, 2024.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Expands office-based treatment options for millions of non-melanoma skin cancer (NMSC) patients
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, announced its Radiant™ Aura treatment solution has received U.S. Food and Drug Administration (FDA) 510(k) clearance. With advanced features for expanded clinical use, simplified patient positioning, and additional patient comfort, Radiant Aura brings radiation therapy to NMSC patients in any dermatology office.
We are delighted to introduce the newest members of our radiation research division: Tim Devling and Levi Vaughan, who we welcome to the company working out of our UK office. Xstrahl has been committed to advancing research excellence for more than a decade,...